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Kidney failure and the gut: p-cresol 
and the dangers from within
M Ketteler1
Previously, uremic toxins were sometimes regarded as a large, 
mysterious, but also anonymous group of factors potentially 
contributing to morbidity and mortality in end-stage renal disease. 
By identifying the protein-bound solute p-cresol as a risk factor for 
mortality in dialysis patients, Bammens and colleagues for the first 
time present evidence of a clinically relevant uremic toxin in relation to 
clinical outcome.
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In 2003, the European Uremic Toxin 
Work Group published a report sum-
marizing the identifi ed uremic retention 
solutes that may or may not be patho-
physiologically relevant in the uremic 
state.1 In this inventory, 22 middle mol-
ecules, 45 water-soluble low-molecular-
weight solutes, and 25 protein-bound 
solutes were listed and discussed with 
regard to their retention characteristics 
and their extracorporeal elimination 
behavior. Th e important activities of the 
European Uremic Toxin Work Group and 
the growing list of candidate factors can 
also be reviewed at http://www.uremic-
toxins.org/. So far, however, most evi-
dence concerning the potential toxicity 
of retention solutes has been generated 
by experimental in vitro and in vivo stud-
ies, whereas most attempts in humans to 
prove relationships between high levels 
of uremic toxins and impaired outcomes 
in the dialysis population have failed or 
have even showed reverse results, as in 
the case of the prototype low-molecular-
weight solute creatinine.2 Still, it is hoped 
that these eff orts will identify modifi able 
factors that may be causally related to 
the excess mortality and, especially, the 
accelerated cardiovascular disease that 
are observed in uremic patients.
Th e study by Bammens et al.3 in this 
issue of Kidney International is the fi rst 
documentation that this hope is prob-
ably justifi ed. Th e investigators included 
175 prevalent hemodialysis patients in a 
prospective observational cohort study 
with a median follow-up of nearly 3 years 
and tested the hypothesis that serum 
levels of p-cresol could predict outcome 
in this cohort. p-cresol is a colonic fer-
mentation product of tyrosine and a 
prototype member of a larger group of 
protein-bound solutes. Protein binding 
of p-cresol and its metabolites (mostly 
p-cresol sulfate) is about 90%, and thus 
these compounds are only marginally 
removable by dialysis techniques. By 
stratifi cation of patients into groups of 
low versus high free p-cresol concentra-
tions using median levels as the cutoff , 
patients with high free p-cresol levels 
were found to have a more than twofold 
increased likelihood of death as com-
pared with patients with low levels. Th e 
authors argue that this was probably a 
group eff ect representing several mem-
bers of a family of protein-bound solutes 
that are characterized by being diffi  cult to 
eliminate as well as diffi  cult to measure.
Th e power of independent risk pre-
diction by free p-cresol serum concen-
trations in this study is solid, but not 
overwhelmingly strong, as risk pre-
diction was signifi cant only when free 
p-cresol was used as a binary, not when it 
was used as a continuous variable. How-
ever, assuming that the p-cresol eff ect 
may potentially be a group eff ect, and 
given the facts that hundreds of diff er-
ent factors and genes are severely dis-
equilibrated in the uremic state and that 
morbidity and mortality in the dialysis 
population are without doubt multifac-
torially determined, the fi ndings of this 
study are quite remarkable.
What could be the pathomechanisms 
by which p-cresol toxicity infl uences sur-
vival in uremic patients? Because accel-
erated atherosclerosis is regarded as one 
of the major determinants of mortality 
in the dialysis population, cardiovas-
cular damage is thought to essentially 
contribute to bad outcomes. Indeed, 
p-cresol was previously shown to cause 
significant endothelial alterations 
including reduction of cytokine-induc-
ible expression of adhesion molecules, 
cytoskeleton reorganization, and 
downregulation of junctional vascular 
endothelial cadherin (VE-cadherin) 
expression leading to increased permea-
bility in vitro.4,5 p-cresol may also impair 
leukocyte function and activation, as was 
recently shown by inhibition of leukocyte 
chemiluminescence production.6 From 
my point of view, the observation by 
Bammens et al.3 of an inverse relation-
ship between free p-cresol and albumin 
levels is interesting in light of p-cresol 
toxicity. On the one hand, lower albu-
min levels, as part of malnutrition syn-
dromes, may favor the availability of free 
p-cresol; but on the other hand, p-cresol 
levels should also be dependent, at least 
to some degree, on protein intake. Th us, 
one may speculate, p-cresol might have a 
direct infl uence on liver protein synthe-
sis, given previous in vitro observations 
that it signifi cantly inhibits hepatocyte 
mitochondrial respiration and thus exerts 
functional hepatotoxicity.7 In addition, 
potential proinfl ammatory properties 
of p-cresol that possibly downregulate 
synthesis of the negative acute-phase 
protein albumin should be evaluated. As 
a number of specifi c toxic p-cresol eff ects 
are well documented, I would currently 
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like to challenge the authors’ interpreta-
tion that p-cresol-related mortality is just 
a group eff ect applying to other protein-
bound solutes, but I prefer to categorize 
this matter as an unsolved issue. Still, the 
in vitro toxicity studies must be supple-
mented and confi rmed by well-defi ned in 
vivo experiments in the future.
Identifying a mortality risk factor in a 
defi ned cohort of patients is one thing; 
treating or at least modifying it is usu-
ally quite another story. In this context, 
the same group of authors presented 
preliminary data during the European 
Renal Association–European Dialysis 
and Transplant Association Congress in 
Istanbul in 2005 showing that p-cresol 
serum concentrations could be eff ectively 
reduced by acarbose treatment in normal 
volunteers8). Acarbose is an α-glucosi-
dase inhibitor commonly used as an oral 
hypoglycemic agent, which blocks the 
hydrolysis of oligo- and polysaccharides 
to glucose. Th is results in higher colonic 
availability of fermentable carbohydrates 
that interfere with and counteract amino 
acid fermentation by several mechanisms. 
As acarbose is essentially nontoxic, this 
may become a harmless and effective 
treatment option to lower production 
of p-cresol at its initial step. However, 
clinical data on the effect of acarbose 
on p-cresol levels in uremic subjects 
are currently lacking, and its effi  cacy in 
these patients may be diff erent from that 
observed in healthy volunteers.
Two other compounds may have 
the potential to bind and thus elimi-
nate intestinally derived toxins such as 
p-cresol: AST-120 (Kremezin) and seve-
lamer. AST-120, available in Japan for 
many years, is an oral carbonaceous 
adsorbent that is thought to be eff ective 
by binding uremic toxins in the intestinal 
tract. Th is binding property was indeed 
demonstrated with regard to indoxyl 
sulfate, another colonic fermentation 
product and protein-bound solute with 
properties similar to those of p-cresol.9 
Recently, benefi cial eff ects of AST-120 
on arterial stiff ness and carotid intima–
media thickness, two relevant surrogate 
parameters of cardiovascular disease, 
were demonstrated in chronic kidney 
disease patients.10 Potential effects of 
sevelamer on uremic toxin absorption 
are currently entirely theoretical, but, 
regarding the structure of the sevelamer 
molecule, unspecifi c binding of factors 
other than phosphate is at least quite 
likely and requires prospective evalua-
tion. A hypothetical schematic concept 
of p-cresol generation and toxicity and 
therapeutic approaches is presented in 
Figure 1.
Should we measure p-cresol levels? In 
my opinion, this relatively small cohort 
study by Bammens et al.3 requires 
confi rmation by larger trials and in dif-
ferent cohorts, including predialysis, 
incident, and peritoneal dialysis patients. 
Th e authors measured p-cresol by gas 
chromatography–mass spectroscopy fol-
lowing deproteinization by acid and heat 
— an appropriate method but not neces-
sarily universally applicable. Further, the 
authors’ argument that p-cresol’s capacity 
to predict mortality risk may be only the 
tip of the iceberg, representing a group 
eff ect of protein-bound solutes, must be 
evaluated by comparison of the predic-
tive strength of comparable factors such 
as indoxyl sulfate or pentosidine.
Nevertheless, this study opens a new 
chapter in research on uremic toxins and 
their pathophysiological importance to 
the uremic disease state. It also tells us 
that there is still a lot we do not know 
about this issue.
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Figure 1 | A hypothetical view of the role of p-cresol as a uremic toxin. p-Cresol is produced in the 
colon and reabsorbed but, because of protein binding, is insufficiently eliminated by hemodialysis 
in uremic patients. High p-cresol levels may cause endothelial or leukocyte dysfunction  and may 
exert proinflammatory and hepatotoxic effects that contribute to increased mortality.
